Bristol-Myers Squibb and Compugen announce clinical collaboration
Bristol-Myers Squibb and Compugen announced a clinical trial collaboration to evaluate afety and tolerability of Compugen’s COM701, an investigational anti-PVRIG antibody, in combination with Bristol-Myers’ PD-1 immune checkpoint inhibitor Opdivo (nivolumab), in patients with advanced solid tumors. October 11, 2018